Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma
Giuseppe Rosiello, Alessandro Larcher, Giuseppe Fallara, et al.
Urologic Oncology Seminars and Original Investigations (2022) Vol. 40, Iss. 6, pp. 271.e19-271.e27
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

The Role of 99mTc‐Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta‐analysis
Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al.
European Urology (2023) Vol. 85, Iss. 1, pp. 63-71
Closed Access | Times Cited: 29
The multispeciality approach to the management of localised kidney cancer
Grant D. Stewart, Tobias Klatte, Laura Cosmai, et al.
The Lancet (2022) Vol. 400, Iss. 10351, pp. 523-534
Open Access | Times Cited: 34
The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
Pooya Dibajnia, Luisa M. Cardenas, Aly‐Khan A. Lalani
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 17
Recurrence after surgery for clear cell and papillary renal cell carcinoma: Head-to head comparison of validated risk scores
Mattia Longoni, Giuseppe Rosiello, Pietro Scilipoti, et al.
Urologic Oncology Seminars and Original Investigations (2025)
Closed Access
Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality–free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients
Mattia Luca Piccinelli, Francesco Barletta, Stefano Tappero, et al.
European Urology Focus (2023) Vol. 9, Iss. 5, pp. 799-806
Closed Access | Times Cited: 7
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy—A large, retrospective, single-center study
Giuseppe Rosiello, Alessandro Larcher, Giuseppe Fallara, et al.
Urologic Oncology Seminars and Original Investigations (2022) Vol. 41, Iss. 3, pp. 149.e17-149.e25
Closed Access | Times Cited: 11
Prognostication for Surgically Treated Papillary Renal Cell Carcinoma: Which Model is the Optimal Choice?
Michele Maffezzoli, Sebastiano Buti
Future Oncology (2024) Vol. 20, Iss. 3, pp. 107-111
Closed Access | Times Cited: 2
Pulmonary lesion after surgery for renal cancer: progression or new primary?
Daniele Cignoli, Alessandro Bandiera, Giuseppe Rosiello, et al.
World Journal of Urology (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 2
Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma
Mattia Luca Piccinelli, Simone Morra, Stefano Tappero, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2155-2155
Open Access | Times Cited: 5
Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
Mattia Luca Piccinelli, Stefano Tappero, Cristina Cano Garcia, et al.
European Urology Open Science (2023) Vol. 53, pp. 109-115
Open Access | Times Cited: 5
Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups
Lorenzo Marconi, Teele Kuusk, Umberto Capitanio, et al.
European Urology Open Science (2022) Vol. 47, pp. 65-72
Open Access | Times Cited: 8
Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers
Andreea Paroşanu, C. Baston, Ioana-Miruna Stanciu, et al.
Diagnostics (2023) Vol. 13, Iss. 14, pp. 2430-2430
Open Access | Times Cited: 4
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus
Pietro Scilipoti, Giuseppe Rosiello, Alessandro Larcher, et al.
World Journal of Urology (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 1
Identifying patients for adjuvant therapy after nephrectomy
Umberto Capitanio, Francesco Montorsi
The Lancet (2022) Vol. 400, Iss. 10358, pp. 1080-1081
Closed Access | Times Cited: 7
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?
Giuseppe Fallara, Alessandro Larcher, Giuseppe Rosiello, et al.
World Journal of Urology (2022) Vol. 40, Iss. 11, pp. 2667-2673
Closed Access | Times Cited: 7
Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy
Cuijian Zhang, Yifan Li, Jinqin Qian, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy
Giuseppe Rosiello, Pietro Scilipoti, Alessandro Larcher, et al.
World Journal of Urology (2023) Vol. 41, Iss. 6, pp. 1573-1579
Closed Access | Times Cited: 3
Establishment and validation of a prognostic nomogram for patients with renal cell carcinoma based on SEER and TCGA database
Changming Wang, Baorui Wu, Deyun Shen, et al.
Translational Cancer Research (2023) Vol. 12, Iss. 6, pp. 1411-1421
Open Access | Times Cited: 3
Differential Prognostic Value of Extrarenal Involvement in Patients With Non-Metastatic Renal Cell Cancer
Giacomo Musso, Giuseppe Fallara, Giuseppe Rosiello, et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 4, pp. e279-e285.e1
Closed Access | Times Cited: 2
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma
Giuseppe Basile, Giuseppe Rosiello, Alessandro Larcher, et al.
Urologic Oncology Seminars and Original Investigations (2022) Vol. 40, Iss. 8, pp. 384.e15-384.e21
Closed Access | Times Cited: 4
Spatial attention wavelon network (SpAWN) for survival-based risk stratification in kidney cancers via CT
Brennan Flannery, Thomas DeSilvio, Amir Reza Sadri, et al.
Medical Imaging 2018: Computer-Aided Diagnosis (2024) Vol. 11, pp. 87-87
Closed Access
THE ROLE OF PROGNOSTIC AND PREDICTIVE MARKERS IN TREATMENT OF NON-SMALL CELL LUNG CANCER
M. A. Krasavina, F.V. Moiseenko
Practical oncology (2024) Vol. 25, Iss. 2, pp. 145-153
Open Access
The Detrimental Effect of Metabolic Syndrome on Long-term Renal Function in Patients Undergoing Elective Partial Nephrectomy for Small Renal Masses
Pietro Scilipoti, Giuseppe Rosiello, Federico Belladelli, et al.
European Urology Open Science (2024) Vol. 69, pp. 73-79
Closed Access
Variability in prognostic models for localized renal cell carcinoma
Thomas Gerald, Vitaly Margulis
Nature Reviews Urology (2022) Vol. 19, Iss. 7, pp. 385-386
Closed Access | Times Cited: 2
SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma
Maria Elena Mantione, Ilenia Sana, Maria Giovanna Vilia, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top